Search

Your search keyword '"oral contraceptive pills"' showing total 3 results
Start Over Descriptor "oral contraceptive pills" Journal journal of the american academy of dermatology
3 results on '"oral contraceptive pills"'

1. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations Part II: Topical, intralesional, and systemic medical management

Author

Alikhan, Ali, Sayed, Christopher, Alavi, Afsaneh, Alhusayen, Raed, Brassard, Alain, Burkhart, Craig, Crowell, Karen, Eisen, Daniel B, Gottlieb, Alice B, Hamzavi, Iltefat, Hazen, Paul G, Jaleel, Tara, Kimball, Alexa B, Kirby, Joslyn, Lowes, Michelle A, Micheletti, Robert, Miller, Angela, Naik, Haley B, Orgill, Dennis, and Poulin, Yves

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Management of diseases and conditions, 7.3 Management and decision making, Administration, Oral, Administration, Topical, Androgen Antagonists, Anti-Bacterial Agents, Canada, Evidence-Based Medicine, Female, Hidradenitis Suppurativa, Humans, Immunosuppressive Agents, Injections, Intralesional, Male, North America, Practice Guidelines as Topic, Prognosis, Publications, Risk Assessment, Treatment Outcome, United States, acne inversa, adalimumab, biomarkers, carbon dioxide laser, clindamycin, comorbidities, ertapenem, finasteride, guidelines, hidradenitis suppurativa, infliximab, laser, lifestyle modification, microbiome, Nd:YAG, oral contraceptive pills, rifampin, spironolactone, Dermatology & Venereal Diseases, Clinical sciences
Abstract

Hidradenitis suppurativa is a severe and debilitating dermatologic disease. Clinical management is challenging and consists of both medical and surgical approaches, which must often be combined for best outcomes. Therapeutic approaches have evolved rapidly in the last decade and include the use of topical therapies, systemic antibiotics, hormonal therapies, and a wide range of immunomodulating medications. An evidence-based guideline is presented to support health care practitioners as they select optimal medical management strategies and is reviewed in this second part of the management guidelines. A therapeutic algorithm informed by the evidence available at the time of the review is provided.

Published
2019

2. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations Part I: Diagnosis, evaluation, and the use of complementary and procedural management

Author

Alikhan, Ali, Sayed, Christopher, Alavi, Afsaneh, Alhusayen, Raed, Brassard, Alain, Burkhart, Craig, Crowell, Karen, Eisen, Daniel B, Gottlieb, Alice B, Hamzavi, Iltefat, Hazen, Paul G, Jaleel, Tara, Kimball, Alexa B, Kirby, Joslyn, Lowes, Michelle A, Micheletti, Robert, Miller, Angela, Naik, Haley B, Orgill, Dennis, and Poulin, Yves

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Anti-Bacterial Agents, Biological Products, Canada, Complementary Therapies, Dermatologic Surgical Procedures, Drug Therapy, Combination, Evidence-Based Medicine, Female, Hidradenitis Suppurativa, Humans, Immunosuppressive Agents, Male, North America, Practice Guidelines as Topic, Publishing, Risk Assessment, Severity of Illness Index, United States, acne inversa, adalimumab, biomarkers, carbon dioxide laser, clindamycin, comorbidities, ertapenem, finasteride, guidelines, hidradenitis suppurativa, infliximab, laser, lifestyle modification, microbiome, Nd:YAG, oral contraceptive pills, rifampin, spironolactone, Dermatology & Venereal Diseases, Clinical sciences
Abstract

Hidradenitis suppurativa is a chronic inflammatory disorder affecting hair follicles, with profoundly negative impact on patient quality of life. Evidence informing ideal evaluation and management of patients with hidradenitis suppurativa is still sparse in many areas, but it has grown substantially in the last decade. Part I of this evidence-based guideline is presented to support health care practitioners as they select optimal management strategies, including diagnostic testing, comorbidity screening, and both complementary and procedural treatment options. Recommendations and evidence grading based on the evidence available at the time of the review are provided.

Published
2019

3. Compliance with pregnancy prevention measures during isotretinoin therapy

Author

Collins, Mary-Katharine, Moreau, Jacqueline F, Opel, Dan, Swan, James, Prevost, Noel, Hastings, Matthew, Schwarz, Eleanor Bimla, and Ferris, Laura Korb

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Prevention, Contraception/Reproduction, Clinical Research, Clinical Trials and Supportive Activities, Behavioral and Social Science, Reproductive health and childbirth, Good Health and Well Being, Abnormalities, Drug-Induced, Acne Vulgaris, Adult, Condoms, Contraception, Contraception Behavior, Contraceptives, Oral, Female, Humans, Isotretinoin, Medication Adherence, Pregnancy, Sexual Abstinence, United States, Young Adult, acne, condoms, contraception, intrauterine device, iPLEDGE, isotretinoin, oral contraceptive pills, Clinical Sciences, Dermatology & Venereal Diseases, Clinical sciences
Abstract

BackgroundApproximately 150 women annually become pregnant while taking isotretinoin despite participation in the iPLEDGE program. Noncompliance with the requirement to be abstinent or use 2 contraceptive methods may be a contributing factor.ObjectiveWe sought to determine the degree of adherence to contraception or abstinence among women taking isotretinoin.MethodsWe conducted an anonymous survey of women of childbearing potential taking isotretinoin for at least 2 months.ResultsAmong 75 participants, 21 (28%) chose abstinence as their primary means of pregnancy prevention, of whom 4 (19%) were sexually active during treatment. The most commonly chosen contraceptive methods among the 39 women who were sexually active were condoms (35, 90%) and oral contraceptive pills (18, 46%). Twelve women (31%) admitted to having intercourse at least once using 1 or fewer forms of contraception; 10 failed to use condoms, and 1 reported completely unprotected intercourse. Among sexually active oral contraceptive pill users, 7 (39%) reported missing 1 or more pills in the previous month.LimitationsData were self-reported, thus participants may have inaccurately reported contraception use.ConclusionsEncouraging the use of highly effective, patient-independent contraception and limiting abstinence to women who have never been sexually active may further reduce the rate of isotretinoin-exposed pregnancies.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results